MX2011012013A - Peptidos ttk y vacunas que incluyen los mismos. - Google Patents

Peptidos ttk y vacunas que incluyen los mismos.

Info

Publication number
MX2011012013A
MX2011012013A MX2011012013A MX2011012013A MX2011012013A MX 2011012013 A MX2011012013 A MX 2011012013A MX 2011012013 A MX2011012013 A MX 2011012013A MX 2011012013 A MX2011012013 A MX 2011012013A MX 2011012013 A MX2011012013 A MX 2011012013A
Authority
MX
Mexico
Prior art keywords
peptides
ttk
methods
antigen
inducing
Prior art date
Application number
MX2011012013A
Other languages
English (en)
Spanish (es)
Inventor
Yusuke Nakamura
Ryuji Ohsawa
Takuya Tsunoda
Sachiko Yoshimura
Tomohisa Watanabe
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2011012013A publication Critical patent/MX2011012013A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2011012013A 2009-05-11 2010-05-10 Peptidos ttk y vacunas que incluyen los mismos. MX2011012013A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21601709P 2009-05-11 2009-05-11
PCT/JP2010/003166 WO2010131452A1 (en) 2009-05-11 2010-05-10 Ttk peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
MX2011012013A true MX2011012013A (es) 2012-02-23

Family

ID=43084837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012013A MX2011012013A (es) 2009-05-11 2010-05-10 Peptidos ttk y vacunas que incluyen los mismos.

Country Status (13)

Country Link
US (1) US8530430B2 (enExample)
EP (1) EP2430039A4 (enExample)
JP (1) JP5786178B2 (enExample)
KR (1) KR20120029394A (enExample)
CN (1) CN102459314B (enExample)
AU (1) AU2010248702A1 (enExample)
BR (1) BRPI1013938A2 (enExample)
CA (1) CA2761393A1 (enExample)
MX (1) MX2011012013A (enExample)
RU (1) RU2531348C2 (enExample)
SG (1) SG175998A1 (enExample)
TW (1) TW201102081A (enExample)
WO (1) WO2010131452A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092634B2 (en) * 2012-09-11 2018-10-09 Oncotherapy Science, Inc. UBE2T peptides and vaccines containing the same
WO2018090257A1 (zh) * 2016-11-16 2018-05-24 深圳华大基因研究院 多肽及其应用
WO2018098636A1 (zh) * 2016-11-29 2018-06-07 深圳华大基因研究院 多肽及其应用
ES2940087T3 (es) * 2017-07-12 2023-05-03 Nouscom Ag Una vacuna universal basada en neoantígenos tumorales compartidos para la prevención y el tratamiento de cánceres con inestabilidad microsatelital (MSI)
CN120712104A (zh) * 2022-10-14 2025-09-26 广东天科雅生物医药科技有限公司 针对神经胶质瘤的肽疫苗及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187548B1 (en) * 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
US20030045491A1 (en) 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
ATE553112T1 (de) 2001-02-21 2012-04-15 Novartis Vaccines & Diagnostic Ttk in der diagnose und als therapeutisches target bei krebs
US7501243B2 (en) * 2001-02-21 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Detection of colon or breast cancer by measuring TTK polypeptide expression
JP2005527180A (ja) 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
WO2003073374A2 (en) * 2002-02-27 2003-09-04 Brands Michael Rik Frans A data integration and knowledge management solution
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
CA2511907A1 (en) 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers
WO2004070062A2 (en) 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050181385A1 (en) 2003-09-22 2005-08-18 Linsley Peter S. Synthetic lethal screen using RNA interference
WO2005073374A1 (ja) * 2004-01-29 2005-08-11 Dainippon Sumitomo Pharma Co., Ltd. 新規腫瘍抗原蛋白質及びその利用
GB0426393D0 (en) 2004-12-01 2005-01-05 Cancer Rec Tech Ltd Materials and methods relating to modulators of spindle checkpoint kinases
RU2403574C2 (ru) 2004-12-08 2010-11-10 Авентис Фармасьютикалз Инк. Способ измерения резистентности или чувствительности к доцетакселу
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
DK2325306T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
EP2305811A1 (en) 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
EP2311986B1 (en) 2005-07-27 2015-04-15 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
JP2010512730A (ja) 2006-12-13 2010-04-30 オンコセラピー・サイエンス株式会社 肺癌の腫瘍マーカーおよび治療標的としてのｔｔｋ
TWI615403B (zh) * 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
CA2708686A1 (en) 2007-12-21 2009-07-02 University Health Network Methods of inhibiting tumor growth using ttk antagonists
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
RU2531348C2 (ru) 2014-10-20
JP5786178B2 (ja) 2015-09-30
CA2761393A1 (en) 2010-11-18
EP2430039A1 (en) 2012-03-21
WO2010131452A1 (en) 2010-11-18
EP2430039A4 (en) 2012-12-05
TW201102081A (en) 2011-01-16
AU2010248702A1 (en) 2011-11-17
US20120135020A1 (en) 2012-05-31
RU2011150283A (ru) 2013-06-20
SG175998A1 (en) 2011-12-29
CN102459314A (zh) 2012-05-16
US8530430B2 (en) 2013-09-10
BRPI1013938A2 (pt) 2019-09-24
CN102459314B (zh) 2016-01-20
KR20120029394A (ko) 2012-03-26
JP2012526519A (ja) 2012-11-01

Similar Documents

Publication Publication Date Title
MX2010014044A (es) Peptidos de epitope cdca1 y vacunas que contienen los mismos.
GB201004575D0 (en) Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
EA202091233A3 (ru) Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка
EP3708185A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
BR112015021828A2 (pt) Peptídeos de kntc2 e vacinas que contêm os mesmos
MX362912B (es) Péptidos ube2t y vacunas que incluyen los mismos.
WO2019197567A3 (en) Antigenic peptides for prevention and treatment of cancer
MX2011012013A (es) Peptidos ttk y vacunas que incluyen los mismos.
PH12014500720A1 (en) Topk peptides and vaccines including the same
EP4219525A3 (en) Foxm1-derived peptide, and vaccine including same
MX2011010191A (es) Peptidos c6orf167 y vacunas que continen los mismos.
EP3981416A3 (en) Koc1-derived peptide and vaccine including same
MX2015007015A (es) Peptidos sema5b y vacunas que contienen los mismos.
BR112013005448A2 (pt) peptídeos de ttll4 e vacinas contendo os mesmos.
EP3848383A3 (en) Urlc10-derived peptide and vaccine containing same
EP4282883A3 (en) Cdca1-derived peptide and vaccine containing same
EP2513136A4 (en) PEPTIDES TMEM22 AND VACCINES COMPRISING THEM
BR112012013371A2 (pt) peptídeo mybl2 e vacinas contendo os mesmos.
MX2012011666A (es) Peptidos cluap1 y vacunas que incluyen los mismos.
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194241A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC
MY194244A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc

Legal Events

Date Code Title Description
FG Grant or registration